Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May:126:102724.
doi: 10.1016/j.ctrv.2024.102724. Epub 2024 Mar 27.

Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

Christopher Grant  1 , Misako Nagasaka  2
Affiliations
Free article
Review

Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer

Christopher Grant et al. Cancer Treat Rev. 2024 May.
Free article

Abstract

Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with EGFR and ALK alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with EGFR-TKI monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed clinical trials and discuss current ongoing trials' potential benefits, challenges, and future directions in the field.

Keywords: EGFR-mutant; NEOADAURA; Neoadjuvant targeted therapy; Osimertinib; Perioperative targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Grant has no potential conflicts to disclose. Dr. Nagasaka has received consulting fees from Cari Life Sciences, honoraria from AstraZeneca, Daiichi Sankyo, Novartis, Lilly, Pfizer, EMD Serono, Regeneron, BMS, Genentech, Mirati, Takeda, Janssen, Blueprint Medicine and travel support from AnHeart Therapeutics.

MeSH terms